Filippo Cremonini, MD
Gastroenterology · Las Vegas, NVNPI 1417098567
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,550 of the $35,954 with a category attached, or 82.2%. 30 manufacturers reported payments, led by Nestle Healthcare Nutrition Inc. at 47.4% of the total. Reporting peaked in 2021 at $18,129 and has fallen 97.6% since, to $441 in 2025. Among gastroenterology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $129.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nestle Healthcare Nutrition Inc.$17K
- AbbVie$13K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Johnson & Johnson$655
- Ironwood Pharmaceuticals, Inc$368
- Sanofi$269
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$29,55082%
- Travel & lodging$7912%
- Food & beverage$5,51215%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nestle Healthcare Nutrition Inc. | 32 | $17,055 |
| AbbVie(2 entities) | 58 | $12,618 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 44 | $3,057 |
| Johnson & Johnson(2 entities) | 35 | $655 |
| Ironwood Pharmaceuticals, Inc | 17 | $368 |
| Sanofi | 12 | $269 |
| Gilead | 5 | $193 |
| Braintree Laboratories, Inc. | 12 | $186 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $185 |
| Enterra Medical, Inc. | 1 | $166 |
| Lilly USA, LLC | 2 | $156 |
| QOL Medical, LLC | 8 | $130 |
| Ferring Pharmaceuticals Inc. | 6 | $111 |
| Merck | 6 | $95 |
| Lucid Diagnostics Inc. | 2 | $91 |
| Phathom Pharmaceuticals, Inc. | 4 | $89 |
| Intercept Pharmaceuticals, Inc. | 5 | $87 |
| Redhill Biopharma Inc. | 4 | $81 |
| Bristol Myers Squibb | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Olympus America Inc. | 3 | $51 |
| Intra-sana Laboratories | 1 | $51 |
| Ardelyx, Inc. | 1 | $32 |
| Celltrion USA Inc. | 1 | $26 |
| Boston Scientific | 1 | $17 |
| Pfizer | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| Capsovision, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,954 in reported general payments places this provider in the 95th percentile of 103 gastroenterology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 28 | $33,733 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 50 | $8,623 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 54 | $3,494 |
| CholestyramineCholestyramine (With Sugar) | 33 | $3,069 |
| Famotidine | 155 | $1,305 |
| Omeprazole | 116 | $1,042 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 41 | $824 |
| Dicyclomine Hcl | 12 | $257 |
| Pantoprazole Sodium | 18 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $12,618 | $33,73328 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $111 | $8,62350 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 103 gastroenterology providers in Nevada.
Other gastroenterology in Las Vegas
- Christian StoneLas Vegas$1.1M
- James HanLas Vegas$47K
- Vijay JayaramanLas Vegas$28K
- Gary ChenLas Vegas$27K
- David ShihLas Vegas$26K
- Noel FajardoLas Vegas$22K
- Frank FarisLas Vegas$14K
- Tarek AmmarLas Vegas$14K
- Eladio CarreraLas Vegas$13K
- Uday SaraiyaLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.